ATE483467T1 - Verfahren zum schutz vor strahlung mit flagellin - Google Patents
Verfahren zum schutz vor strahlung mit flagellinInfo
- Publication number
- ATE483467T1 ATE483467T1 AT04813124T AT04813124T ATE483467T1 AT E483467 T1 ATE483467 T1 AT E483467T1 AT 04813124 T AT04813124 T AT 04813124T AT 04813124 T AT04813124 T AT 04813124T AT E483467 T1 ATE483467 T1 AT E483467T1
- Authority
- AT
- Austria
- Prior art keywords
- flagellin
- protection against
- against radiation
- modulators
- radiation
- Prior art date
Links
- 108010040721 Flagellin Proteins 0.000 title 1
- 230000005855 radiation Effects 0.000 title 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 2
- 108010057466 NF-kappa B Proteins 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4748—Details p53
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52646003P | 2003-12-02 | 2003-12-02 | |
US52666603P | 2003-12-02 | 2003-12-02 | |
US52649603P | 2003-12-02 | 2003-12-02 | |
US52646103P | 2003-12-02 | 2003-12-02 | |
PCT/US2004/040753 WO2005056042A2 (en) | 2003-12-02 | 2004-12-02 | Methods of protecting against radiation using flagellin |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE483467T1 true ATE483467T1 (de) | 2010-10-15 |
Family
ID=34682348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04813124T ATE483467T1 (de) | 2003-12-02 | 2004-12-02 | Verfahren zum schutz vor strahlung mit flagellin |
Country Status (19)
Country | Link |
---|---|
US (2) | US11235028B2 (de) |
EP (1) | EP1706133B1 (de) |
JP (1) | JP4750716B2 (de) |
KR (1) | KR101287905B1 (de) |
CN (1) | CN1913915B (de) |
AT (1) | ATE483467T1 (de) |
AU (1) | AU2004296828B2 (de) |
CA (1) | CA2547869C (de) |
DE (1) | DE602004029500D1 (de) |
DK (1) | DK1706133T3 (de) |
EA (1) | EA010291B1 (de) |
HK (1) | HK1102492A1 (de) |
IL (1) | IL175974A (de) |
PL (1) | PL1706133T3 (de) |
PT (1) | PT1706133E (de) |
SG (2) | SG176524A1 (de) |
SI (1) | SI1706133T1 (de) |
UA (1) | UA83272C2 (de) |
WO (3) | WO2005057218A2 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1838340B1 (de) | 2004-12-22 | 2018-04-04 | Cleveland Clinic Foundation | Mit flagellin verwandte polypeptide und ihre verwendungen |
MX2007015834A (es) | 2005-06-13 | 2008-09-15 | Cleveland Biolabs Inc | Metodos de proteccion contra apoptosis utilizando polipeptidos. |
SI2194987T1 (sl) | 2007-09-10 | 2016-10-28 | Boston Biomedical, Inc. | Novi inhibitorji poti stat3 in inhibitorji matičnih celic raka |
WO2009102818A1 (en) * | 2008-02-11 | 2009-08-20 | Cleveland Biolabs, Inc. | Method for reducing the effects of chemotheraphy using flagellin related polypeptides |
CN102170911B (zh) | 2008-08-01 | 2014-07-02 | 克里夫兰生物实验室公司 | 用于治疗再灌注损伤的方法 |
KR101254244B1 (ko) * | 2010-11-01 | 2013-04-12 | 한국원자력의학원 | TGF-β1을 유효성분으로 함유하는 방사선 피폭 또는 조사에 의한 세포손상의 예방 또는 치료용 조성물 |
KR20140030132A (ko) | 2011-01-10 | 2014-03-11 | 클리브랜드 바이오랩스, 아이엔씨. | 암을 치료하기 위한 톨-유사 수용체 효능제의 용도 |
CN102965386A (zh) * | 2011-09-02 | 2013-03-13 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法 |
AU2014250940A1 (en) | 2013-04-09 | 2015-10-22 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
KR20150085146A (ko) * | 2014-01-13 | 2015-07-23 | 한국원자력의학원 | 소포체 스트레스 저해제를 포함하는 방사선 방호용 조성물 |
EP3174893B1 (de) | 2014-07-30 | 2020-05-06 | Genome Protection, Inc. | Flagellinzusammensetzungen und verwendungen |
US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
KR101634380B1 (ko) | 2015-06-23 | 2016-06-28 | 한국생산기술연구원 | Tlr5 아고니스트 단백질의 생산방법 |
SG11201804894XA (en) * | 2015-12-16 | 2018-07-30 | Hoffmann La Roche | Improved recombinant production method |
JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
CN112203675A (zh) * | 2018-04-24 | 2021-01-08 | 基因组保护股份有限公司 | 用于改善虚弱和衰老的方法 |
KR102524577B1 (ko) * | 2019-04-22 | 2023-04-21 | 전남대학교산학협력단 | 플라젤린 융합 단백질 및 이의 용도 |
KR20220052300A (ko) * | 2020-10-20 | 2022-04-27 | 전남대학교산학협력단 | 플라젤린 융합 단백질 및 이의 용도 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399494A (en) | 1983-03-04 | 1995-03-21 | The University Of Maryland System | Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom |
US6130082A (en) * | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
US20020009747A1 (en) * | 1997-08-25 | 2002-01-24 | Freda Diane Miller | Methods and reagents for identifying modulators of neuronal apoptosis |
US7300749B2 (en) * | 2000-02-17 | 2007-11-27 | Millennium Pharmaceuticals, Inc. | Molecules of the pyrin domain protein family and uses thereof |
AU2002216500A1 (en) * | 2000-11-28 | 2002-06-11 | Genesis Research And Development Corporation Limited | Methods for modulating apoptotic cell death |
US20030077262A1 (en) * | 2001-10-02 | 2003-04-24 | Guido Franzoso | Methods and compositions for modulating apoptosis |
US7078165B2 (en) * | 2003-03-27 | 2006-07-18 | Institut Pasteur | Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof |
US7638485B2 (en) | 2003-12-02 | 2009-12-29 | Cleveland Biolabs, Inc. | Modulating apoptosis |
EP1838340B1 (de) | 2004-12-22 | 2018-04-04 | Cleveland Clinic Foundation | Mit flagellin verwandte polypeptide und ihre verwendungen |
-
2004
- 2004-12-02 KR KR1020067010934A patent/KR101287905B1/ko active IP Right Grant
- 2004-12-02 SG SG2011087681A patent/SG176524A1/en unknown
- 2004-12-02 WO PCT/US2004/040579 patent/WO2005057218A2/en active Application Filing
- 2004-12-02 SG SG200809013-6A patent/SG148215A1/en unknown
- 2004-12-02 EA EA200601079A patent/EA010291B1/ru not_active IP Right Cessation
- 2004-12-02 PL PL04813124T patent/PL1706133T3/pl unknown
- 2004-12-02 CN CN2004800412595A patent/CN1913915B/zh active Active
- 2004-12-02 CA CA2547869A patent/CA2547869C/en active Active
- 2004-12-02 DK DK04813124.7T patent/DK1706133T3/da active
- 2004-12-02 UA UAA200607304A patent/UA83272C2/uk unknown
- 2004-12-02 WO PCT/US2004/040753 patent/WO2005056042A2/en active Application Filing
- 2004-12-02 PT PT04813124T patent/PT1706133E/pt unknown
- 2004-12-02 EP EP04813124A patent/EP1706133B1/de active Active
- 2004-12-02 SI SI200431577T patent/SI1706133T1/sl unknown
- 2004-12-02 DE DE602004029500T patent/DE602004029500D1/de active Active
- 2004-12-02 AU AU2004296828A patent/AU2004296828B2/en not_active Ceased
- 2004-12-02 AT AT04813124T patent/ATE483467T1/de active
- 2004-12-02 WO PCT/US2004/040750 patent/WO2005056055A2/en active Application Filing
- 2004-12-02 JP JP2006542849A patent/JP4750716B2/ja not_active Expired - Fee Related
-
2006
- 2006-05-28 IL IL175974A patent/IL175974A/en active IP Right Grant
-
2007
- 2007-07-25 HK HK07108097.8A patent/HK1102492A1/xx not_active IP Right Cessation
-
2019
- 2019-07-31 US US16/527,770 patent/US11235028B2/en active Active
-
2021
- 2021-12-21 US US17/557,438 patent/US20220105155A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL175974A0 (en) | Methods of protecting against radiation using flagellin | |
DE60037394D1 (de) | VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE | |
AU2209800A (en) | Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia | |
WO2009038720A3 (en) | Method and apparatus for applying light therapy | |
AU5338301A (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
DE60335293D1 (de) | Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen | |
BR0315359A (pt) | Aparelho médico em forma de bainha, aparatos e método de uso destes | |
DE10084338T1 (de) | Verfahren und Vorrichtung zum Erzeugen und Aufrechterhalten von therapeutischer Hypothermie | |
DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
MY138059A (en) | Use of ikb-kinase inhibitors in pain therapy | |
BRPI0515518A (pt) | análogos de loxapina e métodos de usos dos mesmos | |
DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
DE69911409D1 (de) | Verfahren zur verringerung der schädlichen wirkungen von bestrahlungstherapie auf tierische haut und schleimhaut | |
AR059945A1 (es) | Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig | |
ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
ATE437653T1 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
ATE394097T1 (de) | Verfahren zur verabreichung von buprenorphin zur behandlung von depression | |
WO2004084943A8 (en) | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation | |
IS6105A (is) | Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4 | |
ATE356994T1 (de) | Screeningverfahren mit pim1-kinase oder pim3- kinase | |
ATE423110T1 (de) | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen | |
DE50111926D1 (de) | Strahlungsanordnung sowie deren Verwendung und Verfahren zur Behandlung von Oberflächen | |
DK1237562T3 (da) | Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme | |
MXPA02004699A (es) | Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1706133 Country of ref document: EP |